Stallergenes Greer leverages open innovation to continue to advance precision medicine for the benefit of patients and healthcare practitioners.
The Group has entered into research collaborations with both academia and research organisations, including:
- Imperial College London (UK), a pioneer and world-leading university in the biomarker field, to identify biomarkers of AIT efficacy and expand knowledge regarding the pathophysiology of allergic diseases and their treatment with AIT.
- Alyatec a contract research organisation based in Strasbourg University Hospital (France), to advance precision medicine in AIT. With this collaboration, Stallergenes Greer aimes to strenghten its precision medicine-based approach and the management of patients with allergies by expanding its knowledge of allergy pathophysiology and endotypes, AIT mode of action and clinical validation.
- Swiss Institute of Allergy and Asthma Research (SIAF), a world-class institution focusing on basic research in the field of allergies and asthma to identify predictive signature patterns for patient stratification.